Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9552MR)

This product GTTS-WQ9552MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15991MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ5291MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ12966MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ337MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ4897MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ3969MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2350MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ8724MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW